Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states

被引:66
|
作者
Wen, Feng [1 ,2 ]
Zheng, Hanrui [2 ,3 ]
Zhang, Pengfei [1 ,2 ]
Liao, Weiting [1 ,2 ]
Zhou, Kexun [1 ,2 ]
Li, Qiu [1 ,2 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China
[2] Sichuan Univ, West China Biostat & Cost Benefit Anal Ctr, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Clin Pharm, Chengdu, Peoples R China
基金
中国国家自然科学基金;
关键词
atezolizumab and bevacizumab; cost‐ effectiveness; first‐ line systemic treatment; unresectable hepatocellular carcinoma; PRIMARY LIVER-CANCER; HEPATITIS-B-VIRUS; THERAPIES;
D O I
10.1111/liv.14795
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims In patients with unresectable hepatocellular carcinoma (HCC), the combination of atezolizumab and bevacizumab improved progression-free survival (PFS) and overall survival compared with sorafenib in the IMbrave150 trial. However, whether the price of the combination could be affordable is unknown. The current study assessed the cost-effectiveness of the combination of atezolizumab and bevacizumab as first-line systemic therapy for patients with unresectable HCC from the Chinese and American payers' perspective. Methods A Markov model was built based on a global, multicentre, open-label, phase III randomized trial (IMbrave150, NCT03434379) that included three states of the patient's health: stable disease (SD), progressive disease (PD) and death. Data for all medical costs were acquired from the Red Book, published literature and West China Hospital. Quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) were the primary outcomes. Sensitivity analyses were performed to evaluate the model uncertainty. Results The treatment consisting of a combination of atezolizumab and bevacizumab yielded an additional 0.53 QALYs compared with sorafenib alone, leading to an ICER of $145,546.21 per QALY in China and $168,030.21 per QALY in the USA, both beyond the willing-to-pay threshold ($28,527.00/QALY in China and $150,000.00 /QALY in the USA). The utility of the PD state was the most influential factor in the Chinese model, and the American model was the most sensitive to the price of sorafenib. The results of the models were robust across sensitivity analyses. Conclusion The combination of atezolizumab and bevacizumab was not a cost-effective strategy for the first-line systemic treatment of unresectable HCC from the Chinese and American payers' perspective.
引用
收藏
页码:1097 / 1104
页数:8
相关论文
共 50 条
  • [31] Outcomes of patients with Child-Pugh B and unresectable hepatocellular carcinoma undergoing first-line systemic treatment with sorafenib, lenvatinib, or atezolizumab plus bevacizumab
    Kikugawa, Chihiro
    Uchikawa, Shinsuke
    Kawaoka, Tomokazu
    Kinami, Takahiro
    Yano, Shigeki
    Amioka, Kei
    Naruto, Kensuke
    Ando, Yuwa
    Yamaoka, Kenji
    Tsuge, Masataka
    Kosaka, Yumi
    Ohya, Kazuki
    Mori, Nami
    Takaki, Shintaro
    Tsuji, Keiji
    Kouno, Hirotaka
    Kohno, Hiroshi
    Morio, Kei
    Moriya, Takashi
    Nonaka, Michihiro
    Aisaka, Yasuyuki
    Masaki, Keiichi
    Honda, Yohji
    Naeshiro, Noriaki
    Hiramatsu, Akira
    Aikata, Hiroshi
    Oka, Shiro
    ONCOLOGY, 2024, 102 (03) : 239 - 251
  • [32] Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis
    Wen, Feng
    Huang, Peng
    Wu, Qiuji
    Yang, Yang
    Zhou, Kexun
    Zhang, Mengxi
    Li, Qiu
    CANCER MEDICINE, 2024, 13 (16):
  • [33] Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma: A cost-effectiveness analysis.
    Wang Wenjun
    Wang Jingjing
    Zhang Xin
    Wang Yikai
    Shi Juanjuan
    Jia Xiaoli
    Dang Shuangsuo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [34] Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
    Shu, Yamin
    Tang, Ying
    Ding, Yufeng
    Zhang, Qilin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 122
  • [35] Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma
    Meng, Rui
    Zhang, Xueke
    Zhou, Ting
    Luo, Mengjie
    Qiu, Yijin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (07) : 1079 - 1086
  • [36] Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Wen, Feng
    Huang, Peng
    Wu, Qiuji
    Yang, Yang
    Li, Qiu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 469 - 469
  • [37] Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma
    Liao, Weiting
    Xu, Huiqiong
    Hutton, David
    Wu, Qiuji
    Yang, Yang
    Feng, Mingyang
    Lei, Wanting
    Bai, Liangliang
    Li, Junying
    Li, Qiu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [38] HIGHER RISK OF PROTEINURIA IN ATEZOLIZUMAB PLUS BEVACIZUMAB THAN LENVATINIB AS A FIRST-LINE SYSTEMIC TREATMENT IN UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Yang, Jiwon
    HEPATOLOGY, 2024, 80
  • [39] First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States
    Sun, Ke-Xin
    Cao, Shan-Shan
    Shi, Feng-Hao
    Guan, Yue
    Tang, Meng
    Zhao, Mei-na
    Jian, Yu-Fan
    Cui, Bin
    Li, Zhi-Yan
    Wang, Jing-Wen
    Yu, Feng
    Ding, Yi
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [40] COST EFFECTIVENESS ANALYSIS OF LENVATINIB FOR THE FIRST-LINE TREATMENT OF INDIVIDUALS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Li, X.
    Wudong, G.
    Wang, Y.
    VALUE IN HEALTH, 2020, 23 : S37 - S37